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Abstract: The 46th EuroCongress on Drug Synthesis and Analysis (ECDSA-2017) was arranged
within the celebration of the 65th Anniversary of the Faculty of Pharmacy at Comenius University
in Bratislava, Slovakia from 5–8 September 2017 to get together specialists in medicinal chemistry,
organic synthesis, pharmaceutical analysis, screening of bioactive compounds, pharmacology and
drug formulations; promote the exchange of scientific results, methods and ideas; and encourage
cooperation between researchers from all over the world. The topic of the conference, “Drug Synthesis
and Analysis,” meant that the symposium welcomed all pharmacists and/or researchers
(chemists, analysts, biologists) and students interested in scientific work dealing with investigations
of biologically active compounds as potential drugs. The authors of this manuscript were plenary
speakers and other participants of the symposium and members of their research teams. The following
summary highlights the major points/topics of the meeting.
Keywords: natural compounds; drug design and development; medicinal chemistry; organic
synthesis; chemical biology; pharmaceutical analysis; new small entities; therapeutic proteins
1. Introduction
P. Mucaji and J. Jampilek
Discoveries within pharmaceutical and biomedical sciences have been increasingly accelerating,
therefore communication among scientists and research teams around the world has become more and
more important. Beyond participation in various scientific databases and portals and other virtual
events, another possibility is attendance at select specialised conferences. The traditional symposium
“Drug Synthesis and Analysis” has a long history. Over the last decades it has been transformed from
a local Czechoslovak, later Czech and Slovak symposium into a conference with several international
keynote speakers to a full-value international conference. Thus, this traditional symposium has
changed to a prestigious international conference that can be found in the worldwide calendar of
conference events as “EuroCongress on Drug Synthesis and Analysis” (ECDSA) [1]. This original
conference and successors are high-quality meetings that cover all the fields of pharmaceutical sciences.
Currently, the main aim of ECDSA is to develop a platform for scientific contacts between researchers
dealing with pharmaceutical sciences from European and other countries around the world and
to support cooperation between scientists in this field. Excellent speakers from all over the world
presented their results at individual sessions of the 46th EuroCongress on Drug Synthesis and Analysis
(ECDSA-2017) that was held in Bratislava, capital of Slovakia, from 5–8 September 2017 [1].
The start of a two-year programme of study in the academic year 1939–1940 was organised by
the Faculty of Arts and the Faculty of Medicine and can be considered an important milestone in
the study of modern pharmacy in Slovakia. Beginning in 1948, the length of study was extended to
four years in Czechoslovakia. The independent Faculty of Pharmacy at Comenius University was
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established by a government regulation that came into effect on 1 September 1952 [2]. Thus, during
this conference, the Comenius University faculty celebrated the 65th anniversary of its establishment.
It was a pleasure and an honour for the faculty to welcome many prestigious scientists as well as many
young researchers and students on the faculty grounds.
This year of the ECDSA conference [1] was devoted to the following research topics: (i) drug
design, research and development; (ii) natural compounds; (iii) structure, function and interactions of
proteins, engineered enzymes; (iv) nucleic acids chemistry; (v) chiral compounds; (vi) structural and
solid state analysis; (vii) drug formulations and drug delivery systems; (viii) chemical biology and
biological chemistry; (ix) pharmacology and ADMET; (x) biomaterials and nanomaterials; (xi) drug
formulations and drug delivery systems; and (xii) pharmaceutical service and history of pharmacy.
The aim of the symposium is to promote the exchange of scientific results, methods and ideas and
encourage cooperation between researchers from all over the world. In total, 190 active participants
from 20 countries around the world presented their novel results.
The authors of this manuscript are plenary speakers and other participants of the symposium
and members of their research teams. The following summary highlights major points and topics of
the symposium. Individual experimental and review contributions/sections are ordered from in-silico
design, synthesis of potential drugs to their analytical characterization and screening of biological
activity. The manuscript closes with hot topics focused on counterfeit drug detection and big data
problems in drug design.
2. Finding In-silico Paradise in Multidimensional QSAR Studies
A. Bak, V. Kozik and K. Sieron
The rational creation of a desired compound pharmacological profile, not the compound itself,
has been a tremendously challenging issue due to the complex nature of the diverse drug–target
interactions ruled by inter/intra-molecular phenomena. This challenging object of interest for
chemists involved in property-based drug discovery can be illustrated by the balance in the molecule’s
pharmacokinetic/pharmacodynamic profile, termed ‘sweet spot,’ between sufficient drug potency
and acknowledged constraints on the physicochemical properties of the drug candidate [3]. The art
of specifying molecules of potential therapeutic value at the ‘pre-synthesis’ stage can be assisted
by computer-aided molecular design (CAMD) techniques for the comprehensive mapping of the
compound topology and/or topography into the property-based chemical space.
Modelling multidimensional quantitative structure-activity relationship (mD–QSAR) techniques
are pragmatic provided that a congeneric series of compounds is proceeded. The analogy is crucial
in chemistry, especially in cases when we do not fully understand the investigated process or effect.
In fact, a variety of protocols have evolved from this concept (1D ÷ 7D–QSAR), however their
practical importance for drug design is still controversial. The a priori calculation of molecular
descriptors, crucial for the compound’s bioavailability and hence critical for the prospective drug
candidate, is necessary to make predictions of a chosen property profile. The pursued target of in-silico
modelling is to produce statistically robust models capable of making accurate quantitative predictions
including binding affinity, metabolic fate and pharmacokinetic or toxicity parameters (ADMET) [4].
The molecular ADMET–tailored properties are essentially estimated, based on the molecular structure,
as ‘intuitive roadmaps’ even before the synthesis of the molecule has been rationalized. Considerable
endeavours have been employed to implement in-silico protocols which resulted in two essential
paradigms classified as ‘indirect’ ligand-based (receptor-independent) and ‘direct’ structure-based
(receptor-dependent), respectively. Regarding a similar property-principle of the quantitative SAR
approach, a ‘reverse’ image of the target binding geometry might be retrieved from the ensemble
of intrinsic and/or extrinsic features of structurally-related (bio)active molecules which share the
same pharmacological pattern [5,6]. A number of 3D–QSAR procedures have been implemented,
however the comparative molecular field analysis (CoMFA) diffused quickly into medicinal and
computational chemistry becoming a cornerstone for computer–aided molecular design. A number of
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alternative CoMFA–like protocols have emerged, e.g., comparative molecular surface analysis (CoMSA)
that implemented improvements in the molecular description, alignment rules and, subsequently,
the modelling performance (predictive quality) [7].
In the broadest sense, 4D–QSAR methodology has evolved from the molecular shape
analysis (MSA) by explicit enhancement of 3D–QSAR approaches, where the substitution of the
single–conformer concept with cube–like structures of different resolution produces a fuzzy pattern of
molecular objects. The 4D–QSAR formalism successfully incorporates some CoMFA characteristics
employing the spatial grid, where the grid cell size is viewed as a ‘methodology parameter’ to produce a
molecular shape spectrum (MSS) according to the trial alignment rule [8]. Moreover, the neural version
of Hopfinger’s cube formalism, namely SOM–4D–QSAR, employing the Kohonen self–organizing
maps has been applied to produce a fuzzy 4D–QSAR–like representation of the conformational space
as an appealing alternative which performs comparably to its grid counterpart [9]. Additionally,
we concentrated on systematic model space inspection by splitting data collection into training/test
subsets to monitor statistical estimator performance in the effort for mapping of the probabilistic
pharmacophore geometry using the stochastic model validation (SMV) approach.
The automated variable reduction with the IVE–PLS procedure represents a sieve for detecting
only those descriptors that have prescribed the greatest individual weighting for the observed cholic
acids analogue activity. The ‘pseudo–consensus’ 4D–QSAR methodology was used to extract an
‘average’ 3D–pharmacophore by exploring various data subpopulations and which embodies the
quantity for a quality argument to indicate the relevant contributing factors of the cholic acid absorption
activity [10]. A comparative structure-affinity study of anthraquinone dye adsorption on cellulose
fibre was performed using receptor-dependent 4D-QSAR methods based on grid and neural (SOM)
methodology coupled with IVE-PLS procedure [11]. The applied RD 4D-QSAR approach focuses
mainly on the ability of mapping dye properties to verify the concept of tinctophore in dye chemistry.
The working paradigm of fragment-based design or fragonomics assumes that well-placed fragments
account for crucial ligand-receptor interactions, while the rest of the molecule mainly serves as a
scaffold that holds the ‘active’ fragments together. Is it possible to experimentally and/or theoretically
tailor protein cavity regions that are important for ligand recognition and specificity, namely a
fragment-based domain design? How can even the vague electrostatic, steric or lipophilic patterns that
govern changes in binding ligands affinity be specified? Hence, the application of the potential that is
represented by libraries of artificial targets binding a given guest molecule in physiological conditions
as a model system for the emulation of ligand-receptor interactions has been reported [12].
Lipophilicity is generally regarded as a first–rate physicochemical parameter increasingly
relevant in characterizing both the pharmacokinetic (ADMET) and pharmacodynamic aspects of
drug–receptor/enzyme interactions, and which often correlates well with the bioactivity of chemicals.
Numerous compounds of different chemical structures were evaluated/applied as absorption
promoters. Cholic acid is one of the most important human bile acids with a range of pharmacological
activities. Various software log P predictors for estimation of the numerical lipophilic values for
a set of cholic acid derivatives have been employed and subsequently crossed-compared with the
experimental parameter (RM). The mean values of the selected molecular descriptors that average
over the chosen calculation methods (consensus clog P) were subsequently correlated with the RM
parameter. To investigate the variations within the ensemble of cholic acid derivatives PCA and SOM
procedures were employed to visualize the major differences in the performance of drug promoters
with respect to their lipophilic profile [13].
In conclusion, a range of calculation methods were employed to analyse the experimental data
using consensus methodology for finding in-silico optimization in multidimensional QSAR studies.
One should be aware that ‘statistical unicorns exist on paper not in reality’, therefore we should not
blindly follow theoretical estimators and sometimes do the experiments [14].
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3. Computational Prediction of Aspartyl(Asparaginyl)-β-Hydroxylase Substrates in Cancer
Signalling Pathways and Implications for Cancer Therapeutics
M. Olsen
Aspartyl(asparaginyl)-β-hydroxylase (ASPH) is a 2-oxoglutarate (2OG) utilizing iron-dependent
dioxygenase closely related to epigenetic enzymes such as KDM, TET1-3, and FTO [15]. ASPH catalyzes
post-translational hydroxylation of critically positioned aspartic acids and asparagines in specific
calcium-binding Epidermal Growth Factor (cbEGF) domains. Biologically, ASPH is involved in
trophoblast invasion of the uterine wall and is expressed in the endoderm of developing embryos
although expression in healthy adult tissue is extremely limited [16]. ASPH has been demonstrated
to activate the Notch signalling pathway both in vitro and in vivo [16]. ASPH inhibitors have been
rationally designed and synthesized, and demonstrate predicted activities in vitro [17], including
suppression of migration, invasion, and activation of NOTCH pathway related proteins. The Notch
signalling pathway has been identified as a key pathway in cancer [18]. In vivo proof-of-principle
experiments demonstrate significant suppression of tumour growth at 1 mg/kg [19].
To investigate the relationship between ASPH and the Notch signalling pathway, computational
prediction of ASPH substrates was performed utilizing the known ASPH hydroxylation recognition
sequence. Both canonical as well as near canonical recognition sequences were evaluated. As illustrated
in Figure 1, nearly all Notch receptors contain potential ASPH hydroxylation sites, as do known Notch
ligands Jagged-1/2, DLL1, DLL4, DNER, DLK1/2. In addition, known Notch pathway modulating
proteins CRB1/2 also contain potential ASPH hydroxylation sites. The results of these computational
predictions enable the creation of new paradigm for cancer therapeutics.
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Figure 1. Presence of multiple canonical Aspartyl(asparaginyl)-β-hydroxylase (ASPH) hydroxylation
sites in all cbEGF containing NOTCH receptors, ligands (JAGGED-1/2) and modulators such as
Crumbs human homologs.
Previous strategies for targeting the Notch signalling pathway, such as γ-secretase inhibitors that
prevent the proteolytic processing of Notch family receptors [20], suffer from severe, dose limiting
gastro-intestinal (GI) toxicity, complicating the clinical potential of this class of agent [21]. However,
ASPH inhibitors do not demonstrate GI toxicity even when administered IP at a dose of 50 mg/kg
every other day. To rationalize this observation, a model for ASPH modulation of the Notch signalling
pathway has been developed as illustrated in Figure 2.
Briefly, normal GI tissue requires a basal level of normal Notch pathway activation. Tumour tissue
expresses ASPH, resulting in hydroxylated Notch receptors, ligands, and perhaps even modulators.
As a consequence, there is a dramatic increase in Notch signalling resulting in intense activation.
A Pan-Notch suppressing strategy, such as gamma-secretase inhibitors, suppresses all Notch activation,
including the basal level of activation required for normal GI function. However, a specific ASPH
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4. Design, Synthesis, and Anti-Cancer Activity of Tetrandrine Derivatives
W. Pan, Y. Liu, S. Hu and J. Lan
Natural products remain the most important source of pharmacological treatments nowadays.
Based on statistics, more than 50% of drugs come from natural products, either natural origins or
derivatives of natural origins [22–24]. One anticancer drug, paclitaxel, has saved or prolonged survival
time since it was commercially introduced into the clinic, and has also attracted many research groups
with the challenge of total synthesis and synthetic process [25,26]. Numerous similar compounds
such as albumin-bound paclitaxel, docetaxel and taxanes are being developed for clinical use [27–30].
Many compounds, especially including natural products, have been studied with the rise of new
mechanisms of cell death.
Alkaloid or alkaloid-containing plants play an important role in medicine for anticancer,
antiarrhythmic, antihypertensive, muscle relaxant and so on [31,32]. Tetrandrine is a typical
bisbenzylisoquinoline alkaloid which raised great attention with its bio-activities such as anti-cancer,
anti-inflammatory, immunologic and antiallergenic effects since it has been isolated from a Chinese
medicinal plant, Stephania tetrandra S Moore [33–36].
Our group previously discovered that the analogues of tetrandrine and fangchinoline showed
potent anticancer activities on different cancer cell lines. As the research of fangchinoline moved along,
we found that fangchinoline could induce human hepatocellular carcinoma cells (HCC) death through
an autophagic mechanism by inducing translocation of p53 and activating AMPK, which is totally
different of tetrandrine [37]. Based on those findings, the derivatization of these two novel natural
products has proceeded, as illustrated in Scheme 1. Over 300 derivatives have been synthesized
based on this family of novel natural products and some of them exhibited much stronger anticancer
activities than the prototype compounds. From these derivatives, the thiourea compound LJJ-104
exhibited strong inhibitory effect on HCC cells with IC50 values of 1.06 µM, which is 15.8-fold
lower than that of the starting material tetrandrine and 30.3-folds than that of the positive control
sorafenib. The mechanism study showed that LJJ-104 was capable of initiating endoplasmic reticulum
stress-associated apoptotic cell death, and activation of JNK and caspase pathways were probably
involved. A derivative of fangchinoline, ZG-01, showed better anti-HCC activity and the mechanistic
study revealed it might induce autophagic cell death as well as HDAC inhibition and anti-CSC activity.
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5. En Route to New Anticancer Agents Based on Alkaloid Luotonin A
N. Haider
Luotonin A is a pentacyclic alkaloid that was first isolated in the late 1990s from the Asian
plant, Peganum nigellastrum Bunge (Zygophyllaceae) [38]. It has a pyrroloquinazolinoquinoline skeleton
and thus shares some basic structural features with camptothecin (CPT, Figure 3). Camptothecin is
well-known because of its pronounced antitumour activity [39]. The latter is based on a stabilising
effect towards the binary complex formed between DNA and the enzyme, topoisomerase I, as an
essential step for releasing the supercoiled structure of the nucleic acid, and this stabilisation effectively
prevents DNA replication. While CPT itself has unfavourable pharmacokinetic properties, some of
its derivatives, such as topotecan and irinotecan, have made their way into clinical use as anticancer
agents for the chemotherapy of certain malignancies [39]. However, these camptothecin derivatives not
only cause the typical side effects of most cytotoxic agents, but also suffer from specific adverse effects
like bladder toxicity [40]. This problem arises from the labile hydroxylactone structure of CPT-like
compounds, which first leads to an undesired early inactivation of the drug by lactone-ring opening
at the physiological blood pH and later (during excretion) to another undesired structural change,
namely re-formation of the lactone in the acidic environment of the urinary bladder. For that reason
(together with synthesis-related aspects), luotonin A has received increasing interest as an alternative
lead structure for the development of therapeutically useful topoisomerase I poisons, as it was found
to exhibit a similar biological activity as CPT, albeit with considerably lower potency [41]. As shown
in Figure 3, luotonin A does not possess the labile lactone structure and, moreover, lacks the chiral
centre of CPT.
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Thus, in recent years quite a number of publications have appeared that describe various total
syntheses of luotonin A as well as some structural modifications of this alkaloid. A comprehensive
2011 review article [41] summarises this development. Some of these synthetic pathways were
used for the preparation of derivatives bearing various substituents mainly at rings A, B and E of the
quinolino[2′,3′:3,4]pyrrolo[2,1-b]quinazoline system. In the Haider research group, two complementary
synthetic strategies have been employed that permit the selective placement of different functionalities
at positions 1, 2, 3, and 4 of the pentacyclic skeleton [42,43]: the “southern route” to 2- or 4-substituted
derivatives makes use of a modified cycloaddition strategy that was first described by Zhou et al. [44]
for the total synthesis of camptothecin and luotonin A; the “northern route” to 1- or 3-substituted
congeners also utilizes an intramolecular [4 + 2] cycloaddition reaction as the key step, but features a
different arrangement of the diene and dienophile components (Scheme 2).
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Scheme 2. Retrosynthetic representation of two orthogonal synthetic routes to A-ring-substituted
derivatives of luotonin A (for clarity, some bond angles in intermediates are drawn incorrectly).
A library of differently substituted derivatives of the alkaloid as well as some heterocyclic
analogues could be prepared by these two routes, but both pathways were also found to have
specific limitations. For instance, N-pyridyl residues are not tolerated as anilide-type synthons in
the “southern route” [42], probably because of preferential attack at the pyridine nitrogen (and not
at the amide oxygen) by the electrophilic phosphorus in bis(triphenyl)oxodiphosphonium triflate
(Hendrickson’s reagent) that is used to promote the final cycloaddition step. A similar regioselectivity
issue was recently observed with anilides bearing an ester group or a cyano group in ortho position,
whereas the para-substituted counterparts smoothly undergo the cycloaddition reaction in the expected
way [45].
Several of the A-ring-modified Luotonin A derivatives that have been synthesised via these two
routes exhibit in vitro growth inhibitory activity towards selected human tumour cell lines with EC50
values in the low micromolar range but so far, no candidate with sub-micromolar activity could be
obtained. In an attempt to further modify the lead structure, nucleophilic displacement of a 4-fluoro
substituent with primary and secondary amines was investigated [46]. Here, an unexpected oxidative
C-ring opening reaction was observed that leads to carboxamides of the general structure shown in
Scheme 3. Interestingly, some of these novel compounds show moderate cytotoxic activity.
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6. Targeting Oncogenic Mutant TP53—One Step Ahead
R. Musiol
Protein p53, encoded by TP53 tumour suppressor gene is one of the most important nodes in cell’s
life and death cycle. It is responsible for response to major stress factors such as electromagnetic
radiation, oxidative stress, DNA damage or metabolic disturbances [47]. In healthy cells p53
is suppressed by endonucleases Mdm2/MdmX through a ubiquitination trigger for proteasomal
degradation. Stress factor phosphorylation stops the Mdm2 protein and activates p53 which
triggers pathways leading to cell cycle arrest, DNA repair or in case of fatal damage; induction
of apoptosis [47–49]. For this reason, p53 has potent control activity in cell development. On the
other hand, Tp53 is also one of the most frequently mutated genes in cancers [50]. It can be found in
roughly half of all cancer cases with high prevalence in breast, lung and colon cancers. Significantly,
the prognosis is often poor in cases with diagnosed p53 mutation [51]. A primary challenge concerning
TP53 mutation is the extremely high variability of the type and position resulting in vast landscape
of mutants. Although the majority of the mutants lose their suppressor functionality, there are also
mutants that acquire even more oncogenic strength—the so-called gain-of-function mutations [52].
The function and prevalence in cancers make p53 a good drug target for anticancer therapy [53].
Various drugs suppressing mutant p53 have been described, however only PRIMA-1 (APR-246) has
reached clinical trials so far [54]. Unfortunately, most p53 targeting drugs seem to be predominantly
selective for specific mutants and they tend to remain inactive in cancers with deletion of Tp53
(p53 null).
During our research, we concentrated on the known styrylquinazoline derivative CP-31398
(see Scheme 4) with p53 reactivating activity. This compound interacts with the DNA-binding domain
of p53 [55,56]. It is also able to increase synthesis of this protein in mutants and in wild type cells.
In p53 deficient cells, this compound is also capable of inducing apoptosis through an independent
pathway; however, the activity is greatly diminished. As presented in Table 1, against p53 null
mutants, the weak anticancer activity of CP31398 results in an unacceptably low therapeutic index
when compared to normal human fibroblasts (GM07492). Given our strong experience in quinoline
derivatives with antifungal [57,58], antimicrobial [59–62] and antiretroviral [63–65] activity, we decided
to pursue our interest in quinolines targeting p53 deficient cells in the search for novel anticancer
agents. Quinoline [66–71] and quinazoline [72] derivatives synthesized in our group showed strong
anticancer activity. Novel compounds designed in this study appeared to be several times more
effective against p53−/− than normal cells. Interestingly, this potency seems to be related with the
intercalating properties of styrylquinolines.
In conclusion, mutations in TP53 could be considered an Achilles heel of cancer. Although the
absence of suppressor proteins opens the way for proliferation and drug resistance, it also makes
the cells more vulnerable to DNA damage. Low concentrations of intercalating agents lead to small
DNA damage. This may be detected and repaired under control of properly functioning p53 protein,
while p53 null mutants suffer from accumulation of these injuries and die much earlier.
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Table 1. Selected activities of styrylquinolines B (R=H, see Scheme 4) against wild type and p53 null
colorectal cancer cells [73].
Compounds Activity IC50 [µM]
No. R1 HCT116 (p53+/+) HCT116 (p53−/−) Therapeutic index *
CP-31398 18.63 ± 0.92 26.28 ± 1.41 0.4
B 2,3-Cl 5.13 ± 1.41 2.99 ± 0.61 >20
B 3,4-Cl 9.41 ± 2.17 3.34 ± 0.58 >8
B 2-F 15.43 ± 2.46 8.38 ± 1.12 >3
* Calculated as IC50p53−/− to normal fibroblasts (GM07492).
7. Highly Anticancer Active Copper(II) Complexes Involving Natural and Nature-Inspired
O,O′-Donor Ligands
J. Vanco
Secondary metabolites of higher plants, such as flavonoids, 2′-hydroxychalcones or β-diketones,
show plenty of important biological activities as well as represent suitable O,O′-chelating ligands for
the preparation of biologically active transition metal complexes.
The recent trends in the design and development of anticancer active coordination compounds
involve several diverse strategies. The efforts to design innovative drugs based on traditional
platinum-based clinically used drugs, such as cisplatin, often fails due to unfavourable benefit/risk
ratio and such new potential drugs already represent only about 20% of all metal-based cancer
therapeutics in ongoing clinical trials [74]. It seems likely that one of the viable routes towards new and
more active cancer therapeutics may be represented by the development of non-platinum coordination
compounds. One of the interesting and prospective groups of non-platinum based biologically-active
compounds is represented by heteroleptic copper complexes. Recently, a member of a group of
mixed-ligand copper(II) complexes, known under the name of Casiopeínas® [75], involving the
combination of heterocyclic diimine N,N′-donor ligands and simple additional N,O- or O,O′-ligands,
made it as far as to Phase 1 clinical trials as a prospective anticancer agent [76].
In an effort to prepare new and more active anticancer mixed-ligand copper(II) complexes,
involving the combination of diimine N,N′-donor ligands and additional O,O′-ligands, we decided
to utilize the nature-inspired O,O′-ligands from the groups of flavonoids, 2′-hydroxychalcones [77]
and their synthetically modified analogues. As the results of our endeavours realized to date, three
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generations of highly biologically interesting compounds were prepared and studied by a series of
chemical, physical and biological tests used to describe their structure, physical, chemical properties
and affinity towards biological targets which enabled us to uncover some mechanisms responsible for
their potent antitumor effects.
The first generation of the mixed-ligand copper(II) complexes (see Figure 4) involved a
combination of 1,10-phenanthroline derivatives and 1-azaflavone-3-ol ones [78,79]. The most active
compounds showed significant cytotoxicity against the panel of human cancer cell lines (A549, HeLa,
G361, A2780, A2780R, LNCaP, THP-1), with IC50 values in the range of 360 nM–3.9 µM, and moderate
toxicity towards primary culture of human hepatocytes, with IC50 values up to 20 µM.
The second generation of the copper(II) complexes (see Figure 4) involved a combination of
1,10-phenanthroline derivatives and 2′-hydroxychalcone derivatives. The most active compounds
showed significant cytotoxicity against the panel of human cancer cell lines (A549, HeLa, G361, HOS,
A2780, A2780R, 22Rv1), with IC50 values in the range of 1.1 µM–9.3 µM, and lower toxicity towards
primary culture of human hepatocytes, with IC50 values up to 64 µM [80].
The third generation of the copper(II) complexes (see Figure 4) involved a combination of
1,10-phenanthroline derivatives and flavonoid derivatives, intrinsically possessing a moderate
anticancer activity. The most active compounds showed significant cytotoxicity against the panel of
human cancer cell lines (A549, MCF-7, HOS, A2780, A2780R, Caco-2), with IC50 values in the range
of 600 nM–5.9 µM, and very low toxicity towards primary culture of human hepatocytes, with IC50
values up to more than 100 µM (limited by the solubility of the compound).
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All three generations of complexes showed the ability to effectively interact with DNA by
intercalative mechanism and act as chemical nucleases in the state of oxidative stress. Moreover,
the compounds were able to interact with the sulphur-containing biomolecules L-cysteine and reduced
glutathione at physiologically relevant conditions by both an oxidative mechanism and by formation
of binary complexes.
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The synergistic anticancer effect of O,O′-ligands in the compounds from the third generation led to
the more pronounced specificity and selectivity of their action towards the various cancer cell lines and
richer spectrum of cellular and molecular effects as compared to previous generations of compounds.
These compounds therefore represent very promising agents for further preclinical testing.
8. Non-Canonical Cell Death Mechanisms as a Pharmacological Target
M. Diederich and S. Ji
Over recent years, drug discovery and development essentially focused on compounds whether
natural or synthetic able to trigger apoptotic cell death. Essential readouts were the coordinated
activation of caspase cascades culminating in PARP-1 cleavage, nuclear fragmentation and pyknosis
followed by a complete elimination of apoptotic bodies formed by this process. Accordingly, drug
development focused on compounds able to activate both extrinsic or intrinsic cell death cascades or
synergistic activation of both. In recent years, potent activators of mitochondrial cell death mechanisms
including clinically used Bcl-2 inhibitors entered clinical trials and were FDA approved. Venetoclax
(Venclexa) is an excellent example of such a synthetic compound targeting Bcl-2 with high specificity
alone or combined to other pharmacologically active compounds [81].
Besides apoptotic cell death, other modalities of cellular demise became progressively better
understood and entered the theatre of potential drug development targets. Controlled necrosis was no
longer considered as a catastrophic potentially harmful mechanism of cell demise but researchers like
Vandenabeele [82] started to investigate closer such mechanisms and derive programmed aspects in
line with the basic principles of programmed cell death coined by Lockshin in the 1960s [83].
Various mechanisms of controlled necrosis were identified recently [84]: Necroptosis is intensively
studied programmed necrosis and RIPK is an initial key regulator to foam necrosome to disrupt
plasma membrane. Besides, a dysregulation of reactive oxygen species (ROS) and Ca2+ homeostasis
largely leads to cell demise. Parthanatos occurs by hyperactivation of PARPs, typically PARP-1,
which is leading to depletion of NAD+ and ATP. PARP-1 is a DNA repair protein and activated by
ultraviolet light, ROS, alkylating agents and Ca2+ signalling pathways. 3-aminobenzamide (3-AB) is a
typical pharmacological inhibitor for this cell death modality. It was recently reported that inhibition
of the xc-cystine/glutamate antiporter induced regulated necrosis by facilitating import of cystine
and export of glutamate. This new regulated necrosis was named oxytosis and triggered lysosomal
membrane permeabilization (LMP) through calpain activation. Such pathways are to become novel cell
death pathways with identifiable pharmacological targets to be exploited for future cancer treatments.
Interestingly these “novel” cell death pathways most frequently lead to potent danger associated
molecular pattern (DAMP) exposure, described by Kroemer as particularly immunogenic as DAMP
release characterized immunogenic cell death or ICD [85].
In conclusion, non-canonical cell death induction culminating in ICD could thus contribute to the
development of anticancer treatments with both a cytotoxic component and an outcome triggering the
essential immune response of patients.
9. Structural Modifications of Pyrazinamide and Pyrazinoic Acid—Rational Design towards
New Potential Antituberculars
J. Zitko
9.1. Introduction
According to the latest WHO Global Tuberculosis Report, estimated 10.4 million people worldwide
developed active tuberculosis (TB) in 2015 [86]. In 2015, TB was the causative agent of 1.4 million
deaths, including 0.4 million deaths in people with HIV/TB co-infection [86]. Since 2015, TB is the
leading cause of death among all infectious diseases. The wide distribution of drug-resistant TB strains
is threatening the TB control policy.
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The first-line antitubercular drug pyrazinamide (PZA) has been in clinical use since 1950’s [87].
Despite its firm position in combination therapy of TB, the mechanism of action (MoA) of PZA is not
yet fully understood. For more than 50 years, PZA was supposed to act by non-specific MoA based
on acid-base properties of its active metabolite - pyrazinoic acid (POA), produced by intracellular
hydrolysis of PZA catalyzed by mycobacterial pyrazinamidase/nicotinamidase (PncA). Intracellular
accumulation of POA leads to acidification of cytoplasm, disruption of membrane potentials and
interferes with processes dependent on proton gradient [88]. This theory was the most-widely accepted
MoA of PZA for a long time. In 2015, this non-specific MoA was challenged by Peterson et al. [89],
who directly measured the intracellular pH of mycobacterial cells cultivated with PZA or POA. They
observed only minor, probably biologically irrelevant, acidification after prolonged cultivation with
PZA/POA at concentration 10-fold higher than reported minimum inhibitory concentrations (MIC).
At concentration of 1× MIC, no acidification was observed. Similarly, no significant disruption of
membrane potential was observed at biologically relevant concentrations of PZA/POA.
Since 2000, four different subcellular targets of PZA and/or POA have been reported. Actually,
the discovery of three of them happened in the last six years (since 2011). The level of proof of
individual proposed targets varies, as well as their usability in rational structure-based drug design
(SBDD) efforts.
9.2. Inhibition of Fatty Acid Synthase Type I
Mycobacterial Fatty Acid Synthase type I (FAS I) produces C16 and C26 fatty acids. Both C16 and
C26 acyl derivatives are then utilized by FAS II system for the synthesis of mycolic acids, specific and
unusually long fatty acids typical for mycobacteria. Fatty acid synthesis is a classical target of antiTB
drugs, as the first-line isoniazid inhibits (after activation) the enoyl-(acyl carrier protein) reductase
(InhA), which belongs to the FAS II system. Inhibition of FAS I as a MoA was proved for PZA, POA,
and simple derivatives such as 5-Cl-PZA or n-alkyl esters of POA. The inhibition of FAS I was proved
by means of enzyme inhibition in whole cells [90,91], inhibition of isolated enzyme [91,92], and gene
resistance studies [93]. The first studies reporting FAS I inhibition as potential MoA of PZA occurred
in 2000 [93], but it was not until 2011 when light was shed on the molecular mechanism of FAS I
inhibition by PZA and related compounds. Sayahi et al. showed by Saturation Transfer Difference
NMR experiments on isolated enzyme that PZA [94] and its derivatives [95] are competitive inhibitors
of FAS I, competing for the binding site of NADPH cofactor. Out of six catalytic domains of FAS I,
only two of them utilize NADPH, namely ketoacyl reductase domain and enoyl reductase domain.
Therefore, according to current knowledge, PZA derivatives interact on molecular level with one or
both of these domains of FAS I. FAS I is a large homohexameric protein (2 MDa), therefore efforts to
obtain crystals of sufficient quality for X-ray diffraction studies we not successful so far. The only 3D
structure of mycobacterial FAS I is a model based on cryo-electron microscopy [96], but this structure
does not have sufficient resolution for direct usage in SBDD methods.
9.3. Inhibition of Trans-Translation
Trans-translation is a process of rescuing ribosomes stalled during faulty translation of mRNA.
As published in 2011, Shi et al. was fishing for the specific target of POA in a smart way [97]. They
covalently bound 5-hydroxypyrazinoic acid (5-OH-POA) to polymer stationary phase. This POA bait
was then used to fish for the target protein in the pool of mycobacterial lysate (affinity chromatography).
The ‘fish’ with the highest affinity to the POA bait was the ribosomal protein S1 (RpsA). Isothermal
titration calorimetry proved POA binding to RpsA. The crucial step of trans-translation is the
RpsA mediated attachment of tmRNA to the translating complex. It was shown that POA inhibits
tmRNA-RpsA association in a dose-dependent manner [97]. As another level of indirect proof of this
MoA, it was found that some PZA-resistant strains of M. tuberculosis possess mutations in rpsA gene [97].
In 2015, Yang et al. deposited an X-ray resolved structure of POA-RpsA complex (pdb: 4NNI) [98].
Interestingly, they observed that two molecules of POA are bound to the surface of RpsA. POA binds
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to the close vicinity of residues that are known to interact with tmRNA, which is in agreement with the
proposed molecular MoA. As visible in Figure 5a (indicated by green arrows), one molecule of POA can
be substituted on C-5 or C-6 of the pyrazine nucleus. As authors logically suggested, these positions
should be substituted with lipophilic substituents to increase the penetration of rather hydrophilic
POA through the mycobacterial cell wall [98].
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Figure 5. Exit vectors indicated by green arrows designate possible structural modifications of
pyrazinamide (PZA) / pyrazinoic acid (POA): (a) POA bound to surface of ribosomal protein S1
(pdb: 4NNI) [98]; (b) PZA docked into catalytic site of pyrazinamidase PncA (pdb: 3PL1).
9.4. Other Specific Targets for PZA
In 2014, it was shown that POA inhibits L-aspartate α-decarboxylase (PanD) of M. tuberculosis [99].
PanD is an important enzyme in pantothenate synthesis. The molecular mechanism of inhibition
is not known, although there were efforts to find the binding site of POA in PanD by molecular
docking combined with molecular dynamics [100]. 3D structure of PanD is available as pdb: 2C45.
Again in 2014, PZA was recognized as an inhibitor of quinolinic acid phosphoribosyl transferase
(QAPRTase) of M. tuberculosis [101]. QAPRTase catalyzes the synthesis of nicotinic acid mononucleotide
from quinolinic acid and 5-phosphoribosyl-1-pyrophosphate, in a biosynthetic pathway leading to
NADH. Molecular docking suggested that PZA can compete for the binding site with the natural
substrate – quinolinic acid [101]. 3D structure of QAPRTase is available as pdb: 1QPO.
9.5. Implications for Structure-Based Drug Design
In recent years, the perception of PZA and its metabolite POA has changed from a non-specific
cytosol acidifier to a multi-target inhibitor of specific mycobacterial enzymes and processes. Current
knowledge of specific targets and availability of their 3D crystallographic structures is a starting
point for rational SBDD to prepare PZA/POA derivatives with improved pharmacodynamical/
pharmacokinetic properties. Often, PZA is a prodrug of POA, which itself is the inhibitor of specific
targets as in the case of RpsA and PanD. FAS I is inhibited by both PZA and POA, as well as by some
simple structural derivatives. Interestingly, QAPRTase is inhibited by PZA but not POA.
As an example of rational design of PZA/POA derivatives, we have designed and prepared
a series of 5- or 6-substituted PZA derivatives, using lipophilic substituents such as alkyl,
alkylamino [102] or alkylamido (C3-C8). The rationale for substitution at C-5 or C-6 on the pyrazine core
is given by interactions of POA-RpsA (Figure 5a). To address the question whether 5- or 6-substituted
PZA can still be hydrolyzed by PncA to the corresponding substituted POA, a molecular docking
study was performed. Preliminary results show that at least some 6-substituted PZA derivatives
(but probably not 5-substituted PZA derivatives) could be substrates of PncA (Figure 5b).
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10. Natural Products Regulating Macrophage Cholesterol Efflux
A.G. Atanasov and D. Wang
10.1. Introduction
Macrophages scavenge the oxidized low-density lipoprotein (ox-LDL) to become cholesterol-laden
“macrophage foam cells” [103]. Macrophage foam cell formation and accumulation in the
subendothelial area of the arterial wall is the hallmark of atherosclerosis [103]. Recent clinical
reports indicated that enhancement of macrophage cholesterol efflux is a promising strategy for
the prevention and treatment of atherosclerosis [104]. Natural products represent an important pool
for the identification of novel drug leads, which is supported by the fact that natural products have
become effective drugs in a wide variety of therapeutic indications, and are broadly studied in the
context of cardiovascular disease therapy in particular [105–108]. Therefore, lots of studies by us and
others have addressed natural products that modulate macrophage cholesterol efflux. In this part of
the manuscript, we summarize interesting studies published in recent years in this research area.
10.2. Flavonoids and Polyphenols
Flavonoids and polyphenols are an important source for seeking natural products with
macrophage cholesterol efflux enhancing capacity. Alpinetin, a natural flavonoid abundantly present
in the ginger family, exhibited positive effects on cholesterol efflux and inhibited ox-LDL-induced lipid
accumulation in ox-LDL-loaded THP-1 macrophages and human monocyte-derived macrophages
(HMDM), which might be through the peroxisome proliferator-activated receptor γ (PPARγ)/liver
X receptor-alpha (LXRα)/ATP-binding cassette transporter A1 (ABCA1)/ABCG1 pathway [109].
Baicalin, a major flavonoid of Scutellaria baicalensis, increased cholesterol efflux from THP-1
macrophages possibly through the PPARγ-LXRα-ABCA1/ABCG1 pathway [110]. In vivo, treatment
with baicalin significantly decreased atherosclerotic lesion sizes and lipid accumulation in
atherosclerosis rabbit carotid arteries [110]. Another study shows that baicalin induced cholesterol
efflux from THP-1 macrophages via the PPARγ/LXRα/SR-BI pathway. Chrysin, a natural flavonoid,
promoted cholesterol efflux from RAW264.7 macrophages, which may be related to up-regulation of
the classical PPARγ-LXRα-ABCA1/ABCG1 pathway [111]. Hesperetin, a citrus flavonoid, promoted
apoA-I-mediated cholesterol efflux from macrophages by increasing ABCA1 expression through
the activation of LXRα and PPARγ [112]. Quercetin, a flavonoid, increased cholesterol efflux from
THP-1 derived macrophages through activating PPARγ-LXRα-ABCA1 pathway [113]. Another study
indicated that quercetin enhanced cholesterol efflux, which was associated with an increase in
ABCA1 mRNA and protein expression through p38-LXRα-dependent pathway [114]. Silymarin
is a hepatoprotective mixture of flavonolignans and flavonoids extracted from the seeds of milk thistle
(Silybum marianum L. Gaertn). Its major constituents, including isosilybin A, silybin B, silychristin and
isosilychristin, promoted cholesterol efflux from THP-1 macrophages via upregulation of the ABCA1
protein levels [115].
Polyphenols beyond flavonoids are also the important source for seeking natural products with
macrophage cholesterol efflux enhancing capacity. Consumption of extra virgin olive oil-enriched
with green tea polyphenols stimulated cholesterol efflux rate from mouse peritoneal macrophages
(MPM) [116]. In vivo experiments indicated that consumption of this extract also reduced
atherosclerotic lesion size of mice significantly [116]. Unfortunately, the authors could not conclude
that the antiatherogenicity of the extract is strictly due to its effect on cholesterol efflux, since
the extract also increased high-density lipoprotein (HDL) cholesterol levels in serum. Paeonol, a
phenolic component purified from Paeonia suffruticosa (Cortex Moutan), enhanced cholesterol efflux
from J774.A1 macrophages by LXRα-ABCA1-dependent pathway [117]. In vivo study also indicated
that paeonol increased protein expression of ABCA1 in apolipoprotein E (apoE) deficient (apoE−/−)
mice [117]. Pomegranate peel polyphenols promoted apoA-I-mediated macrophage cholesterol efflux
Molecules 2017, 22, 1848 16 of 38
from RAW264.7 macrophages by up-regulating ABCA1 and LXRα at the mRNA and protein levels,
with independence on ABCG1 and PPARγ [118].
10.3. Carotene and Its Derivatives
9-cis-Retinoic acid, which is synthesized primarily intracellularly from retinaldehyde that can
be produced from β-carotene, induced macrophage cholesterol efflux via the LXRα-dependent
up-regulation of ABCA1 and ABCG1 [17]. 9-cis-Retinoic acid also reduced the atherosclerotic plaque
area in the aortic sinus of apoE−/− mice [119]. 9-cis-β-carotene, a precursor for 9-cis-Retinoic-acid, as
well as all-trans-β-carotene significantly increased cholesterol efflux from RAW264.7 macrophages,
which might be ascribed to transcriptional induction of ABCA1, ABCG1, and apoE [120]. Astaxanthin,
one of the naturally occurring carotenoids, increased ABCA1/G1 expression, thereby enhancing
apoA-I/HDL-mediated cholesterol efflux from RAW264.7 cells in a LXR-independent manner [121].
10.4. Fatty Acids
Dietary consumption of fatty acids has been reported to be related to atherosclerosis [122].
13-hydroxy linoleic acid, a natural PPAR agonist, induced cholesterol efflux from RAW264.7
macrophages via the PPARα/β-LXRα-ABCA1/SR-BI-pathway [122]. Elaidic acid, the most abundant
trans-fatty acid in partially hydrogenated vegetable oil, slightly increased ABCA1-mediated cholesterol
efflux, while oleic acid led to decreased ABCA1-mediated efflux [123]. Elaidic acid was shown to
stabilize macrophage ABCA1 protein levels in comparison to that of its cis-fatty acid isomer, oleic
acid, which accelerated ABCA1 protein degradation [123]. Linoleic acid (18:2), an unsaturated fatty
acid, attenuated HDL-mediated cholesterol efflux from murine bone marrow-derived macrophages
(BMDM) through down regulation of ABCA1 mRNA and protein levels but not through changes in
LXRα or sterol receptor element binding protein (SREBP)-1 expression.
10.5. Other Compounds
Curcumin from the rhizomes of Curcuma longa affected the cholesterol efflux from adipocytes
by regulating the PPAR-LXR-ABCA1 pathway [124]. It is also demonstrated that curcumin
enhanced cholesterol efflux from macrophage via suppressing the JNK pathway and activating
the LXR-ABCA1/SR-BI pathway [125]. Furthermore, curcumin enhanced cholesterol efflux by
upregulating ABCA1 expression through activating AMP-activated protein kinase (AMPK)-SIRT1-
LXRα signalling in THP-1 macrophage-derived foam cells [126].
Falcarindiol and other polyacetylenes have been demonstrated to act as agonists of PPARγ, an
important transcriptional regulator of cholesterol efflux [127,128]. Interestingly, falcarindiol increased
ABCA1 protein level and macrophage cholesterol efflux not just by activating PPARγ and following
promotion of ABCA1 gene expression, but also by a second complementary mechanism involving
inhibition of ABCA1 protein degradation [129].
Danshensu, the major water-soluble component extracted from Salvia miltiorrhiza Bunge
(Danshen), promoted cholesterol efflux from RAW264.7 macrophages by the upregulation of the
cellular cholesterol exporters ABCA1 and ABCG1 [130]. Diosgenin, a structural analogue of cholesterol
from Danshen, enhanced ABCA1-dependent cholesterol efflux and inhibited aortic atherosclerosis
progression by suppressing macrophage miR-19b expression in human THP-1 macrophages and
MPMs [131]. Salvianolic acid B, also known as lithospermic acid B or tanshinoate B isolated from
Danshen, promoted cholesterol efflux from THP-1 macrophages through the PPARγ/LXRα/ABCA1
pathway [132].
Arctigenin, a bioactive component from Arctium lappa, promoted cholesterol efflux from
ox-LDL-loaded THP-1 macrophages through upregulation of ABCA1, ABCG1 and apoE, which
was dependent on the enhanced expression of PPARγ and LXRα [133]. Citrulline, which is unusually
abundant in watermelon (Citrullus vulgaris), increased ABCA1 and ABCG1 mRNA and protein levels
in THP-1 macrophages and monocyte-derived macrophages, translating into enhanced apoA-I- and
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HDL-mediated cholesterol efflux [134]. Emodin, an anthraquinone derivative isolated from the
roots of Rheum palmatum, enhanced cholesterol efflux by activating PPARγ in ox-LDL-loaded THP1
macrophages [135]. Erythrodiol from olive oil promoted cholesterol efflux from THP-1-derived
macrophages by stabilizing the ABCA1 protein [136]. Leoligin, a natural lignan found in Edelweiss
(Leontopodium nivale ssp. alpinum), induced cholesterol efflux from THP-1-derived macrophages by
upregulating ABCA1 and ABCG1 expression [137]. Piperine, the principle pungent constituent of the
fruits of Piper nigrum L., promoted cholesterol efflux from THP-1-derived macrophages probably via
interference with the calpain-mediated ABCA1 degradation pathway [138]. Puerarin, the effective
component isolated from the Chinese herb Pueraria lobate, promoted ABCA1-mediated cholesterol
efflux and decreased intracellular cholesterol levels through the pathway involving miR-7, STK11, and
the AMPK-PPARγ-LXRα-ABCA1 cascade [139]. Spiromastixones 6 and 14, which are from a deep
sea-derived fungus (Spiromastix sp. MCCC 3A00308), stimulated cholesterol efflux to apoA-I and HDL
in RAW264.7 macrophages through upregulation of PPARγ and ABCA1/G1 [140]. Vitamin D, a group
of fat-soluble secosteroids, stimulated cholesterol efflux through induction of CYP27A1 expression via
a vitamin D receptor-dependent c-Jun N-terminal kinase (JNK) 1/2 signalling pathway and increase of
27-hydroxycholesterol levels, which induced LXR, ABCA1 and ABCG1 expression [141].
Sesamol and sesame (Sesamum indicum) oil enhance macrophage cholesterol efflux via
up-regulation of PPARγ1 and LXRα transcriptional activity in a MAPK-dependent manner [142].
Sesamin, an active constituent of Sesamum indicum, enhanced cholesterol efflux from RAW264.7
macrophages probably through upregulation of the PPARγ-LXRα-ABCG1 pathway [143]. Another
study suggested that sesamin improved macrophage cholesterol efflux through PPARγ1-LXRα
and MAPK signalling [144]. Vascular smooth muscle cells (VSMC) also can form foam cells via
accumulation of cholesterol. 17β-Estradiol promoted cholesterol efflux from VSMC and reduced
VSMC-derived foam cell formation via LXRα-dependent upregulation of ABCA1 and ABCG1 [145].
Bilirubin, a strong antioxidant, decreased macrophage cholesterol efflux from cholesterol-loaded
THP-1 macrophage foam cells, which was associated with decreased ABCA1 protein expression [146].
Nicotine, an important component in tobacco, suppressed cholesterol efflux from HMDM by inhibiting
LXR pathway [147].
10.6. Conclusions
Natural products from traditional medicine and food represent an important pool for the
identification of compounds with cholesterol efflux enhancing capacity. In this part of the manuscript,
we summarize compounds with various kinds of chemical structure including flavonoids, polyphenols,
and fatty acids, carotene and its derivatives, and lignin, etc., which could regulate cholesterol efflux
from macrophages. The mechanisms of increased cholesterol efflux by these natural compounds
include regulation of PPARγ-LXRα-ABCA1/ABCG1/SR-BI pathway, p38-LXRα-ABCA1 pathway,
AMPK-SIRT1-LXRα-ABCA1 pathway, and AMPK-PPARγ-LXRα-ABCA1 pathway.
11. Trends in Design of Novel Ligands for Treatment of Neurodegenerative Diseases
D. Agbaba, K. Nikolic, S. Oljacic and J. Vucicevic
11.1. Introduction
Pathophysiological mechanisms of neurodegenerative diseases (such as Alzheimer’s Disease
(AD) and Parkinson’s Disease (PD)) are based mostly on very complex deregulation of cholinergic,
adrenergic, dopaminergic, serotonergic, glutamatergic, and histaminergic neurotransmitter systems.
Pathophysiology of AD also includes formation of the β-amyloid fibril deposits and β-amyloid
oligomers. Current therapeutic strategies for the treatment of AD are based on acting on one drug
target only and therefore show limited efficacy in modifying the disease. Since AD is a complex
multi-factorial disease with various clinical symptoms, such as multiple cognitive deficits affecting
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memory, attention and language, development of an efficient therapy is very challenging [148]. The lack
of efficacy of the single-target approach observed so far has led to the development of the multi-target
drug design and polypharmacological drug discovery approach [149,150].
11.2. Design of Novel Ligands
Current trends in design and discovery of novel ligands for the treatment of neurodegenerative
diseases are based on discovery of a set of drug targets for these diseases and on development
of ligands with an optimal action on a few drug targets. Computational approaches such as
data mining/repurposing, ligand/structure-based drug design, and in-silico screening are very
successfully used for the design of the multi-target drugs with a desired activity profile. The in-silico
methods are very useful in the discovery and optimization of novel ligands with an enhanced affinity
to a set of the drug targets, as well as in optimization of physicochemical and pharmacokinetic
properties of the multipotent drug candidates [151]. The ligand based virtual screening study [152,153]
was successfully applied for lead optimization of the two donepezil hybrid compounds with the
previously confirmed MAO-A, MAO-B, AChE, and BuChE inhibiting properties [154] (Figure 6).
The pharmacophore analysis was performed to define the molecular determinant of these donepezil
hybrids, to propose structural modifications that would increase inhibition of the enzymes, and to
evaluate activities of the designed hybrids [152,153]. The main chemical diversities, pharmacophores
and pharmacological profiles of the agents acting as a histamine H3R antagonist/inverse agonist and
dual H3R antagonist/inverse agonist with an inhibiting effect on acetylcholine esterase, histamine
N-methyltransferase, and the serotonin transporters were successfully developed in a few recent
studies [155,156].
11.3. Conclusions
Neurodegenerative diseases such as AD and PD are multifactorial complex diseases affecting
several related pathological pathways. Multi-target drug design is a promising approach in modern
medicine for complex diseases. The new challenge is to define optimal combinations of the drug
targets able to enhance the efficacy of the therapy.Molecules 2017, 22, 1848 18 of 37 
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demanding stress situations occurring in the everyday life. New drugs are needed to improve
the treatment of the negative consequences of stress exposure, such as anxiety and depression.
We have identified a new target for future psychotropic drug development, namely the modulation of
adrenocortical steroid aldosterone action in the brain. We have presented original data on anxiogenic
and depressogenic action of aldosterone in animals [160] as well as changes in aldosterone release in
patients with high trait anxiety and major depressive disorder [161,162].
Another new target for anti-depressant drug development is the β3-adrenergic receptor.
The β3-adrenergic receptor is a frequently investigated target for pharmaceutical chemists and the
derivatives of β3-adrenergic receptor agonists are being developed for their antioxidant, antimicrobial
and other actions. A doctoral thesis on the synthesis and analysis of derivatives with potential action
on β3-adrenergic receptors performed at the Department of Pharmaceutical Chemistry, Faculty of
Pharmacy of the Comenius University in Bratislava [163,164] has motivated our research group
to focus on the potential role of β3-adrenergic receptors in the stress response. In spite of the
fact that catecholamines belong to the main stress hormones and they are acting via adrenergic
receptors, no information has been available on possible changes of the β3-adrenergic receptors under
stress conditions. We have provided the first evidence of stress-induced increase in β3-adrenergic
receptor gene expression in the brain [165]. The stress model used was repeated immune challenge in
rats, induced by administration of increasing doses of lipopolysaccharide (LPS). LPS treatment was
associated with body weight loss and increased anxiety-like behaviour. In LPS-treated animals of both
sexes, β3-receptor gene expression was increased in the prefrontal cortex but not in the hippocampus.
Cortical β3-receptors may be related to stress-induced behavioural changes [165].
In conclusion, β3-adrenergic receptors may represent new target also for drugs acting in the
brain to induce anxiolytic action. However, potential efforts towards new drug development require
additional obtaining and synthesis of knowledge.
13. Biomimetic Chromatography as a User-Friendly Technique in Drug Discovery
A. Tsantili-Kakoulidou, F. Tsopelas and C. Giaginis
The development of biomimetic chromatography offers valuable support in multi-objective
optimization (MOO) approaches, providing a significant advance for rapid experimental–based
estimation of ADME properties. Biomimetic properties, defined as the retention outcome of
biomimetic chromatography, mimic the biophase either by incorporation (immobilization) of a
biological agent in a chromatographic column, or by creation of analogous conditions using appropriate
mobile phase additives (surfactants), while they take advantage of the experimental simplicity and
reproducibility of chromatographic techniques [166]. They are considered to be positioned in the
interface between physicochemical properties (lipophilicity) and in vitro end-points. Biomimetic
chromatography incudes immobilized artificial membrane (IAM) chromatography, biopartitioning
micellar chromatography, mainly for permeability studies and protein-based chromatography-human
serum albumin (HSA) and α1-acid glycoprotein (AGP) chromatography for plasma protein
binding studies.
There are two commercially available IAM columns, IAM.PC.MG and IAMPC.DD2, which
contain phosphatidylcholine, immobilized on a propylamino-silica gel skeleton. They differ in
the end-capping procedure and show comparable performance. Both contain charged centers
(phosphate anions and positively charged choline nitrogen) and glycerol carbonyls, which may affect
solute retention, by developing electrostatic and hydrogen bonding interactions respectively [166].
However, partitioning in the IAM hydrophobic core remains the main process in retention
mechanism. Thus, IAM retention factors encode more complex information than traditional
octanol- water distribution coefficients log D and may be considered as a border case between
passive diffusion and binding to membranes or tissues, a process associated with the concept
of phospholipophilicity [166,167]. In most cases IAM retention, expressed by retention factors
(log kwIAM), is not used as a stand-alone parameter and additional descriptors, molecular weight
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and/or hydrogen bond descriptors are incorporated in the relevant models, always with a
negative sign.
We have derived successful non-linear models (R = 0.892) for % human oral absorption (%HOA)
for 63 structurally diverse drugs, which are not substrates for uptake or efflux transporters, by
combining IAM retention factors (measured at pH 5.5 and 7.4 for bases and acids respectively) with
molecular weight, Abraham’s hydrogen bond acidity parameter (both with negative sign) and fraction
of protonated species (F+). The negative sign of the latter indicates an overexpression of electrostatic
interactions of solutes with IAM phosphate anions, which was also evident in IAM retention/liposome
partitioning correlation. The model has been successfully validated with a blind test of 22 drugs [168].
In biopartitioning micellar chromatography (BMC) a reversed-phase stationary phase is used.
Micelle formation is achieved by adding a surfactant solution above the critical micellar concentration
(CMC) as mobile phase additive. Dependent on the type of the surfactant used (neutral, anionic,
cationic) different secondary interactions may be developed, while reduced ionization is observed
in the micelle environment. Successful application of BMC for human intestinal absorption and for
blood-brain barrier permeability has been reported [169].
Protein–based biomimetic chromatography, using a stationary phase with immobilized HSA,
offers a friendly alternative for rapid plasma protein binding (PPB) measurements, since HSA is the
most important plasma protein [166]. Like for HSA in solution, affinity to HSA column is favoured by
acidic drugs. It is well documented that immobilization of HSA does not alter its binding characteristics
and many % HSA data, used for screening or QSPR studies, have been determined by HSA-based
high-performance liquid chromatography (HPLC). We have demonstrated that isocratic log k10HSA,
measured at 10% acetonitrile as organic modifier in the mobile phase for 52 structurally diverse drugs,
produce a 1:1 correlation with affinity constants log K, calculated from % PPB [170].
Columns containing the second critical plasma protein, AGP, are also commercially available.
They show higher affinity for basic drugs—however, their performance in simulating binding to AGP
is not well established. Displacement experiments for cross-linked AGP stationary phases have shown
differences in the binding properties as compared to the behaviour of AGP in solution, while the
presence of two genetic variants (F1*S and A) is an additional difficulty. We have obtained moderate
relationships between AGP retention factors and affinity constants log K for F1*S variant or considering
the sum of log K for both variants, upon introduction of Abraham’s basicity descriptor as additional
parameter (R = 0.832 and R = 0.807 respectively [171].
However, we have derived a sound relationship for total plasma protein binding (R = 0.949)
combining both HSA and AGP retention factors for 18 structurally diverse, mainly basic, drugs:
log K(plasma) = 0.77 log kw(HSA) + 0.24 log kw(AGP) − 0.56. The regression coefficients reflect the
different volume ratio of the two proteins in plasma. Beyond passive diffusion, IAM retention factors
may also express tissue binding. Ongoing studies indicate that the combination of IAM with HSA
retention factors may simulate pharmacokinetic parameters like volume of distribution or unbound
fraction in brain, which are related to permeability as well as to protein and tissue binding.
14. Chromatography in Analytical Separations of α-Amino Acids
T. Kowalska and M. Sajewicz
14.1. Introduction
Coded (or primary, or proteinogenic) amino acids include nineteen α-amino acids and one imino
acid, and they constitute an alphabet for all proteins. They differ only in the structure of the side
chain, R (as indicated in Figure 7) and all of them (except glycine) have the L-configuration. Coded
amino acids can be classified according to various different criteria, and one classification system is
based on chemical nature of the side chain, R. Thus, we distinguish coded α-amino acids with the
non-polar side chain (8 compounds), the neutral polar side chain (7 compounds), and the charged
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polar side chain (5 compounds). The other group are the non-coded (or non-protein, or non-standard)
amino acids that are neither found in proteins assembled during protein biosynthesis, nor generated
by posttranslational modifications. Hundreds of such amino acids are known and a large number of
these are also α-amino acids. Most non-coded amino acids can be found in plants and microorganisms,
and some of them are of great biological importance as peptide antibiotics (e.g., nisin, alamethicin,
etc.). There are the four main technological approaches to obtaining the monomeric amino acids on
an industrial scale: (i) by the extraction of individual proteinogenic α-amino acids from the protein
hydrolyzates (for this purpose, the hydrolyzates of human hair as raw material are most frequently
used); (ii) by chemical synthesis (in these technologies, crude oil is the main substrate); (iii) by the
procedures with selected enzymes serving as biocatalysts; and (iv) by fermentation (in these procedures
one needs exclusively sugar and a given bacterium type to obtain a single optically pure α-amino
acid) [172,173].
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14.2. Main Focuses on α-Amino Acids
Proteinogenic α-amino acids have attracted the attention of the scientific world mainly as the
simplest building blocks of peptides and proteins, when determination of the primary structure thereof
is considered (through the α-amino acid sequencing). As classical chromatographic techniques do
not play a key role in decoding the primary structures of peptides and proteins, we will refrain from
including this subject matter in our current considerations.
Other important areas of the application of chromatographic techniques to amino acid research
are: (i) the search for traces of life in extraterrestrial regions; (ii) dating of fossilized biological remnants
in paleontology; and (iii) using amino acids as an inexpensive pool for the enantioresolution studies. In
this latter case, either the racemic α-amino acid mixtures represent a resolution problem to be solved,
or the optically pure α-amino acids serve as chiral selectors enabling enantioresolution of the other
racemic mixtures.
The search for extraterrestrial traces of life and more precisely, for extraterrestrial samples of
proteinogenic α-amino acids has been carried out both on Earth and in the interplanetary regions.
Among the most spectacular investigations were those of the huge Murchison meteorite containing
over 15 amino acids, some of them representing basic components of life [174]. Another spectacular
effort was undertaken by the Rosetta mission of the European Space Agency (ESA), targeting the comet
67P/Churyumov-Gerasimenko (nicknamed Chury). The Philae lander (which after ten years traveling
eventually reached the Chury comet on 11 November 2014) was equipped with several miniaturized
gas chromatography-mass spectrometry (GC-MS) systems implemented with the gas chromatographic
capillary columns prepared to resolve and identify proteinogenic α-amino acids (see Figure 8) [175].
Dating of fossilized biological remnants in paleontology with use of proteinogenic α-amino
acids is based on the so-called geochronological clock. Its principle is that with a few important
exceptions, living organisms keep all their amino acids in the L-configuration. When an organism
dies, control over the configuration of the amino acids ceases, and the ratio of D- to L-moves from a
value near 0 towards an equilibrium value near 1, in a process of racemization. The fastest racemizing
and hence, the most frequently used α-amino acid is aspartic acid, with its half-life (t1/2) estimated
as equal to 15.000 ÷ 20.000 years. The concept of geochronological clock was first developed by
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Bada et al. [176], but later—due to certain inconsistencies in the results obtained with its use—the
amino acids racemization data started to be correlated with an outcome of some other dating methods,
e.g., based on the kinetics of the 14C isotope decay in the deceased and fossilized organisms.
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14.3. Chromatography in Enantioreolution and Enantioseparation of α-Amino Acids
Among the most challenging tasks in chromatographic analysis is the enantioresolution and
enantioseparation of the α-amino acid pairs. Enantioresolution is done in a direct way, using
a chiral chromatographic system, whereas enantioseparation is done in an indirect way, using a
non-chiral chromatographic system and the pre-column derivatization. In GC, the predominant
approach is enantioresolution of a racemate, mainly with use of the three commercially available chiral
stationary phase (CSP) types (the hydrogen-bonding type CSPs, the coordination type CSPs, and the
cyclodextrin type CSPs). Perhaps it is noteworthy that all three types of the GC stationary phases
were used in the Rosetta mission [173]. In HPLC, the predominant approach is enantioseparation
with pre-column derivatization, using the Marfey’s reagent (MR) or its analogs [177]. Basic assets of
all these derivatization reagents are that their synthesis runs practically stoichiometrically and they
practically do not racemize in the course of synthesis. Thin-layer chromatography (TLC) is the most
flexible analytical technique out of these three, and it can be used both for enantioresolution and
enantioseparation of the racemic α-amino acid mixtures (and of other low molecular weight chiral
carboxylic acids), offering a unique potential to devise and in-home prepare various different CSPs of
the experimenter’s own choice [177].
14.4. Discovery of Spontaneous Oscillatory Reactions
An unprecedented performance of TLC as a tool for the enantioresolution of the low molecular
weight chiral carboxylic acids (α-amino acids, hydroxy acids and profen drugs) enabled us a discovery
of the two novel classes of spontaneous oscillatory reactions, i.e., spontaneous oscillatory chiral
conversion and spontaneous oscillatory condensation (in the case of α-amino acids, peptidization
(e.g., [178–180]). This discovery made with use of TLC was later confirmed by more sophisticated
(i.e., highly instrumental) analytical tools. Figure 9 provides schematic representation of the oscillatory
changes of a chiral compound’s position on the thin-layer chromatogram in the function of sample
storage time (t), which correspond with the periodic chiral conversion from (+) to (−) and back.
A detailed molecular mechanism of chiral conversion is schematically presented in Scheme 5 upon an
example of L-phenylalanine (L-Phe).
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14.5. Conclusions
Discovery of spontaneous oscillatory chiral conversion and oscillatory peptidization with α-amino
acids has a potential to affect the present-day ideas concerning biogenesis and the evolutionary
concepts. It certainly undermines the importance of geochronological clock. It clearly shows that a
lot more effort has to be invested in future research on physicochemical properties of the monomeric
α-amino acids.
15. Towards Complete Identification of Drugs of Abuse
J. Silberring, P. Mielczarek and M. Smoluch
Novel psychoactive substances (NPS) comprise compounds belonging to two major groups,
named Designer drugs and Legal highs. While the first class requires skills in chemical synthesis,
the latter can be prepared from the over the counter, legal substances and their preparation can be
maintained by an inexperienced teenager, following recipes broadly available on the internet. The scale
of seized samples creates an urgent need to develop fast and unambiguous analytical techniques for
identification of a large number of such substances in a short time. Moreover, most of such compounds
reaching the illegal market [181] generate metabolites of completely unknown function(s) and toxicity
on human body. Yet another issue are by-products of various chemical reactions. Adulterants are also
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frequently added to enhance the strength of a drug or to increase weight of a dose. Altogether, the
final effect may lead to serious consequences, including death.
The majority of diagnostic approaches are based on rapid tests, specific for several groups of
substances most commonly sold on the market. Examples include cocaine, cannabinoids, opiates,
and amphetamines. This indicates that a vast majority of compounds escape selective detection. As
it is quite frequent that the drug sold under a given name may contain quite different substance
(e.g., Ecstasy/MDMA is estimated to contain other chemicals in ca. 50% deliveries!), therefore there
is an urgent need to develop fast, robust, and unambiguous analytical methods to cope with these
problems. Additionally, ER admissions for unknown substances constantly increases as they arrive
on the market, and patients, as well as ER personnel, are unaware of their content, which cannot be
identified by routine analyses.
Here, we propose a general and, in our opinion, complete strategy to solve the above problem.
We are also aware, that analytical sciences will always be a step behind skilful chemists synthesizing
novel substances. The output, however may at least serve as predictive toxicology approach to more
accurately monitor the entire drug profile.
Figure 10 shows a scheme where, in addition to the bioactive substance, the metabolites generated
in the organism [182], together with adulterants and by-products, are taken into consideration. Bearing
in mind that the amount of novel compounds reaching the market (not necessarily illegal) rapidly
increases every year. Some of these drugs disappear from the market as soon they are classed as
illegal. Thus, it is extremely difficult to cope with the large number of analytical procedures that, in
a short time frame may be redundant. A combination of mass spectrometry equipped with ambient
ion sources together with fast metabolic studies, may serve as a preliminary approach to assist more
detailed work. Among the ion sources that do not require sample preparation are ambient plasma
ionization techniques, such as FAPA, DBDI, DART [183]. In vitro generation of potential metabolic
products can be achieved within minutes in the electrochemical cell [184], which substantially increases
capabilities of the entire analytical procedure. Such products generated by electrochemistry may be
screened for eventual toxicity using various cell cultures. The entire analytical strategy should be
perceived as an initial approach, prior to more advanced research.
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16. Application of XRD and DSC Methods for Identification of Counterfeit Drugs
I. Jendrzejewska
A significant increase in the availability of drugs, especially the possibility to purchase medical
preparations in shops, at petrol stations or on the Internet, creates the possibility for introducing
counterfeit drugs, which can contain inappropriate substances, abnormal amounts of active substances
or significant amount of impurities. Counterfeit pharmaceuticals may threaten health and life, and for
this reason, it is important to monitor and investigate compositions of pharmaceutical materials using
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various techniques, such as diffraction, thermal analysis, spectroscopy, etc. The combination of two or
more investigative methods allows for confirmation of the authenticity of a drug.
To check the presence of API (active pharmaceutical ingredient) in common drugs and dietary
supplements, a combination of PXRD (powder X-ray diffraction) and DSC (differential scanning
calorimetry) methods was used. For this study, the selected over-the-counter medicines and dietary
supplements containing acetylsalicylic acid and ascorbic acid were chosen. The PXRD is a fast, reliable
and easy to use technique, which can be used in forensic science to analyse various types of trace
evidence [185]. Most often, the X-ray powder diffraction is used for phase identification of crystalline
materials and to gain information about structural parameters [186]. Crystalline materials have distinct
PXRD spectra and can be identified within a compound or mixture using a database of known PXRD
spectra [187]. Thermal analysis is a branch of materials science where the properties of materials are
studied as they change with temperature. The differential scanning calorimetry measures the rate
of heat flow to a sample and a standard that are at the same temperature. The PXRD measurements
were carried out using a Philips PW1050 diffractometer, whereas the DSC measurements were done
using a DSC-TG Labsys Evo system. These samples were investigated in a polycrystalline form.
For the interpretation of the obtained diffraction patterns, the X-ray structural analysis based on ICDD
PDF-2 was used [188]. The PXRD analysis confirmed that in all investigated samples, the active APIs
(acetylsalicylic acid (ASA) and ascorbic acid (AA)) was present. For some medicines, the diffraction
lines of other APIs were observed in their diffraction patterns (Figure 11).
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Figure 11. Diffraction patterns for drugs containing (a) acetylsalicylic acid (ASA); (b) ascorbic acid (AA).
The phase analysis was done based on ICDD Cards: No. 00-001-0182 for ASA and No. 00-022-1559
for AA. The diffraction patterns are best reported using interplanar distance dhkl rather than the value
of 2θ angle. The peak position at 2θ angle depends on instrumental characteristic such a wavelength.
The peak position as dhkl is an intrinsic, instrument-independent, material property. The Bragg’s Law
was used to convert observed 2θ position to dhkl:dhkl = nλ/2sinθ (where n—diffraction order, λ—X-ray
Molecules 2017, 22, 1848 26 of 38
wavelength, θ—angle of reflection). The values of dhkl for the studied samples are in good accordance
with those presented in the ICDD database (Figure 12).
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The intensities of the diffraction lines depend on the content of the component in the tested
preparation. Therefore, different intensities of lines for the APIs were observed in the obtained
diffraction patterns. The thermal analysis was carried out for drugs containing ASA. This analysis
showed a weight loss of about 5%, which can indicate a thermal dissociation with a loss of CO2 or
H2O, or emission of gaseous products [189]. The observed shift for the endothermic peak in the DSC
curves, towards a lower temperature, indicates the presence of other components (i.e., excipients) or
impurities in the investigated samples in comparison with pure acetylsalicylic acid (Figure 13).
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Based on the above investigation, it can be stated that a combination of the two methods: XRD and
DSC can be used to distinguish original drugs from counterfeit products, e.g., by checking for the
presence of the correct API or by a comparison of the drugs fingerprint.
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17. Big Data Problem in Drug Design
J. Polanski
It is generally believed that big data brings new value and innovation. For example, Szlezak et al.
cited the recent McKinsey research that suggests that the potential use of the big data in the US health
care could reduce costs by $300 billion a year [190]. Accordingly, do we need big data in drug design
and does this method bring new prospects into pharmaceutical business? The answer seems to be
positive. However, despite high expectations the number of big data approaches in drug design are
surprisingly low.
What is big data and how important is big data in drug design? What are the methods that are
used for big data analyses? The structure of big data that are used in drug design has been recently
analysed by Polanski [191] who indicated several basic big molecular data types. Basically, these are
the big data that are generated by descriptor (DE) or property (PE) expansion. There are several typical
architectures of potential big data analyses in drug design:
1. The expansion of the number of descriptors typical in QSAR investigations;
2. The analyses of all available property data. Typical examples are IC50 vs. MW statistics for all
pharmaceutics or drug candidates;
3. The expansion of the number of properties; e.g., in the polypharmacology concept.
QSAR (ad point 1) operates on a well described data architecture usually generating a number of
descriptors for a compound series of 20–100 compounds with a known activity. The analysis of the
complete population, i.e., no sampling, meets one of the requirements of big data. Molecular populations
in drug design are limited, e.g., we have 1564 approved drugs, 1836 targets, 11,387 drug-target
interactions (DrugBank 5.0.3) [192]. Accordingly, although the analysis of all possible data in the
architecture (ad point 2) does not focus on extremely high numbers, to some extent this reminds big
data. Molecular statistics is a term that can describe such analyses [193]. Molecular statistics can result
in important conclusions in drug design, such as for example:
- Commercial drugs usually have lower MW that drug candidates; this is known under the
molecular obesity or slim pharma concept [194,195];
- There is no correlation between IC50 of drugs and their therapeutic dose [196];
- The majority of commercial drugs in new classes are developed by phenotypic (new classes) or
target based (known classes) screening [197];
- The IC50 of drugs is similar to normal distribution [198];
- IC50 of drug candidates (CHEMBL) increases with the increase of MW and log P [196];
- Ligand efficiency [195] does not provide a measure of the ligand-target binding power but
is dominated by the Avogadro type statistics determining a number of molecules in a 1 g
sample [199,200].
Eventually, real big data in drug design needs measured property data. Properties, however, are
seldom available. This means that the PE data are usually getting bigger not by the number of property
types but by an increase in the number of chemical compounds that are annotated with a single property
type. However, even such data are usually limited in numbers, e.g., in a virtual HTS screening of
1.5 million real commercial compounds recorded in Enamine database a set of 1140 compounds with
determined HIV-1 IN inhibition fetched from the ChEMBL v.12 has been used for guiding the activity
pattern [65]. We should realize from the definition of big data by Oxford Dictionaries that data are
getting especially bigger while recording human behaviour and interactions. This can be understood
when we compare a population of the factually registered molecules, i.e., ca. 150,000,000 chemical
compounds, with the much larger population of humans counting ca. 7 billion people. This decides
that the human population provides more complex data then the molecular one. Accordingly, although
the relationship between a chemical structure and its physical or chemical properties is an essential
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concept in chemistry, it is the market formed by human interactions that brings big data and eventually
decides the success of any pharmaceutical. Therefore; we need economic considerations to fully
understand a fate of a drug. Economic behaviour, in particular, a price of a drug is an example of the
nonbinding parameter important for molecular design. Is there any relationship between a chemical
structure of a drug and its economic potential? On the one hand, explaining economic effects is an
extremely complex issue. On the other hand, little market data is available for drugs. The problem
remains unexplored. Instead, a structure-economy relationship method has been recently developed
to analyse a big data for a large library of 2.5 million synthetic building blocks [193].
Formally, all the examples discussed above are architectures of the type (ad point 2). It is
however, architecture (ad point 3) that brings a real breakthrough in the design opportunity. In this
context, the polypharmacology inspired scheme of lipidomics has been developed recently by Gabriele
Cruciani group [201]. The method is limited by an inexpensive and rapid procedure for the extraction
and MS based determination of a medium size population of lipid species that can characterize the
complex answer of any organism for a drug (drug candidate) administration. In 20 min this provides
us a data on the serum concentration of 1000 different lipids in serum. Such a data can be arranged in a
fingerprint-like lipid profile which if tested as a function of time, can give us a real big data presenting
useful information on the activity and toxicity of the xenobiotics used. This illustrated that more
efficient big data investigations are limited not necessarily by the statistical issues but by new methods
in inexpensive property measurements [202]. New HTS methods for property measurements should
undoubtedly bring new quality in big data analyses in drug design.
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